NASDAQ:ANABAnaptysBio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AnaptysBio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $21.24 -1.29 (-5.73 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$21.19Now: $21.24▼$22.6450-Day Range$18.53MA: $20.63▼$23.2452-Week Range$10.00Now: $21.24▼$56.72Volume154,800 shsAverage Volume356,357 shsMarket Capitalization$579.43 millionP/E RatioN/ADividend YieldN/ABeta0.93 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd., including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022), and an anti-LAG-3 antagonist antibody (TSR-033); and an inflammation partnership with Celgene Corporation, including an anti-PD-1 checkpoint agonist antibody (CC-90006) in clinical development. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingAnaptysBio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.00, AnaptysBio has a potential upside of 69.5% from its current price of $21.24.Amount of Analyst CoverageAnaptysBio has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesAnaptysBio has received 322 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAnaptysBio has received 246 “underperform” votes. (Add your “underperform” vote.)Community SentimentAnaptysBio has received 56.69% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote “Outperform” if you believe ANAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 14.00% of the stock of AnaptysBio is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AnaptysBio are expected to decrease in the coming year, from ($2.09) to ($3.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.16 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANAB Previous Symbol CUSIPN/A CIK1370053 Webwww.anaptysbio.com Phone858-362-6295Debt Debt-to-Equity RatioN/A Current Ratio15.96 Quick Ratio15.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$8 million Price / Sales72.43 Cash FlowN/A Price / Cash FlowN/A Book Value$14.93 per share Price / Book1.42Profitability EPS (Most Recent Fiscal Year)($3.60) Net Income$-97,340,000.00 Net MarginsN/A Return on Equity-19.95% Return on Assets-18.65%Miscellaneous Employees78 Outstanding Shares27,280,000Market Cap$579.43 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:ANAB Rates by TradingView Receive ANAB News and Ratings via Email Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions How has AnaptysBio's stock been impacted by COVID-19 (Coronavirus)? AnaptysBio's stock was trading at $15.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ANAB shares have increased by 39.5% and is now trading at $21.24. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of AnaptysBio? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AnaptysBio. When is AnaptysBio's next earnings date? AnaptysBio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for AnaptysBio. How were AnaptysBio's earnings last quarter? AnaptysBio Inc (NASDAQ:ANAB) posted its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.33. The biotechnology company had revenue of $15 million for the quarter, compared to analyst estimates of $10 million. View AnaptysBio's earnings history. What price target have analysts set for ANAB? 8 Wall Street analysts have issued 12-month price objectives for AnaptysBio's shares. Their forecasts range from $12.00 to $140.00. On average, they expect AnaptysBio's stock price to reach $36.00 in the next year. This suggests a possible upside of 69.5% from the stock's current price. View analysts' price targets for AnaptysBio. Has AnaptysBio been receiving favorable news coverage? News headlines about ANAB stock have been trending very negative this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AnaptysBio earned a news impact score of -3.8 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about AnaptysBio. Who are some of AnaptysBio's key competitors? Some companies that are related to AnaptysBio include SAGE Therapeutics (SAGE), Turning Point Therapeutics (TPTX), IGM Biosciences (IGMS), Principia Biopharma (PRNB), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Ligand Pharmaceuticals (LGND), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Xencor (XNCR), I-Mab (IMAB), Aurinia Pharmaceuticals (AUPH), Intra-Cellular Therapies (ITCI) and Myovant Sciences (MYOV). View all competitors. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include Crispr Therapeutics (CRSP), ImmunoGen (IMGN), Editas Medicine (EDIT), NVIDIA (NVDA), Amarin (AMRN), Alibaba Group (BABA), bluebird bio (BLUE), Baozun (BZUN), Canopy Growth (CGC) and Clovis Oncology (CLVS). Who are AnaptysBio's key executives? AnaptysBio's management team includes the following people: Mr. Hamza Suria, Pres, CEO & Director (Age 43)Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 44)Prof. Marco Londei, Chief Medical Officer (Age 62)Mr. Eric J. Loumeau, Gen. Counsel (Age 56)Dr. Hemant Kumar, Sr. VP of Manufacturing When did AnaptysBio IPO? (ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is AnaptysBio's stock symbol? AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB." How do I buy shares of AnaptysBio? Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AnaptysBio's stock price today? One share of ANAB stock can currently be purchased for approximately $21.24. How big of a company is AnaptysBio? AnaptysBio has a market capitalization of $579.43 million and generates $8 million in revenue each year. The biotechnology company earns $-97,340,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. AnaptysBio employs 78 workers across the globe. What is AnaptysBio's official website? The official website for AnaptysBio is www.anaptysbio.com. How can I contact AnaptysBio? AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected] This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
